» Articles » PMID: 27992602

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the Gp41 Trimer

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2016 Dec 20
PMID 27992602
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Structural rearrangements of HIV-1 glycoprotein Env promote viral entry through membrane fusion. Env is a symmetric homotrimer with each protomer composed of surface subunit gp120 and transmembrane subunit gp41. Cellular CD4- and chemokine receptor-binding to gp120 coordinate conformational changes in gp41, first to an extended prehairpin intermediate (PHI) and, ultimately, into a fusogenic trimer-of-hairpins (TOH). HIV-1 fusion inhibitors target gp41 in the PHI and block TOH formation. To characterize structural transformations into and through the PHI, we employed asymmetric Env trimers containing both high and low affinity binding sites for individual fusion inhibitors. Asymmetry was achieved using engineered Env heterotrimers composed of protomers deficient in either CD4- or chemokine receptor-binding. Linking receptor engagement to inhibitor affinity allowed us to assess conformational changes of individual Env protomers in the context of a functioning trimer. We found that the transition into the PHI could occur symmetrically or asymmetrically depending on the stoichiometry of CD4 binding. Sequential engagement of multiple CD4s promoted progressive exposure of individual fusion inhibitor binding sites in a CD4-dependent fashion. By contrast, engagement of only a single CD4 molecule led to a delayed, but symmetric, exposure of the gp41 trimer. This complex coupling between Env-CD4 interaction and gp41 exposure explained the multiphasic fusion-inhibitor titration observed for a mutant Env homotrimer with a naturally asymmetric gp41. Our results suggest that the spatial and temporal exposure of gp41 can proceed in a nonconcerted, asymmetric manner depending on the number of CD4s that engage the Env trimer. The findings have important implications for the mechanism of viral membrane fusion and the development of vaccine candidates designed to elicit neutralizing antibodies targeting gp41 in the PHI.

Citing Articles

The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs.

Qi Y, Zhang S, Wang K, Ding H, Zhang Z, Anang S Commun Biol. 2025; 8(1):442.

PMID: 40089599 DOI: 10.1038/s42003-025-07852-z.


Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.

Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F J Virol. 2024; 98(12):e0172024.

PMID: 39508605 PMC: 11650979. DOI: 10.1128/jvi.01720-24.


Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.

Zhang S, Anang S, Zhang Z, Nguyen H, Ding H, Kappes J J Virol. 2024; 98(10):e0063124.

PMID: 39248459 PMC: 11495050. DOI: 10.1128/jvi.00631-24.


Intermediate conformations of CD4-bound HIV-1 Env heterotrimers.

Dam K, Fan C, Yang Z, Bjorkman P Nature. 2023; 623(7989):1017-1025.

PMID: 37993719 PMC: 10686819. DOI: 10.1038/s41586-023-06639-8.


Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.

Zhang Z, Wang Q, Nguyen H, Chen H, Chiu T, Smith Iii A J Virol. 2023; 97(9):e0059223.

PMID: 37696048 PMC: 10537687. DOI: 10.1128/jvi.00592-23.


References
1.
Melikyan G, Markosyan R, Hemmati H, Delmedico M, Lambert D, Cohen F . Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol. 2000; 151(2):413-23. PMC: 2192659. DOI: 10.1083/jcb.151.2.413. View

2.
Salzwedel K, BERGER E . Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc Natl Acad Sci U S A. 2000; 97(23):12794-9. PMC: 18843. DOI: 10.1073/pnas.230438497. View

3.
Wild C, Oas T, McDanal C, Bolognesi D, Matthews T . A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A. 1992; 89(21):10537-41. PMC: 50374. DOI: 10.1073/pnas.89.21.10537. View

4.
Ray N, Harrison J, Blackburn L, Martin J, Deeks S, Doms R . Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007; 81(7):3240-50. PMC: 1866075. DOI: 10.1128/JVI.02413-06. View

5.
Cai L, Gochin M, Liu K . Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem. 2011; 11(24):2959-84. PMC: 3220743. DOI: 10.2174/156802611798808497. View